Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Harrow Health, Inc.NASDAQ: HROW

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $5.9M rose 94.8% year over year, ahead of the +17.2% change in trailing-twelve-month research & development. Sequentially, it rose 80.1% from the prior quarter. Over 3 fiscal years it compounded at +61.5% a year.

Context

  • Research & development amounted to 4.7% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +94.8% holds above the trailing-twelve-month pace of +17.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.9M+80.1% QoQ
Last fiscal yearDec 2025
$12.85M+5.0% YoY
LTMMar 2026
$15.36M+17.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+94.8%——
1 year+5.0%——
3-year CAGR+61.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
12.85M USD
Year-over-year change
+5.0%
4-year CAGR
+3.8%

Research & Development vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.2% is the 5th highest of 8, against a peer median of +23.6%.
  • Research & development amounts to 5.7% of revenue for HROW, versus a peer median of 1752.3%.
HROW Competitors
Research & Development for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$404M USD+12.5%+6.5%7.6%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$234.61M USD+45.4%+64.5%3080.9%
OCULOcular Therapeutix, Inc.LTM Mar 2026$220.45M USD+47.2%+54.5%423.6%
KODKodiak Sciences Inc.LTM Sep 2026$208.43M USD+23.6%-12.0%—
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$115.59M USD+83.0%+14.7%16.9%
OCSOculis Holding AGLTM Mar 2026CHF 56.48M CHF+0.9%+34.9%11206.4%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$21.25M USD-43.8%+8527.1%6378.2%
HROWHarrow Health, Inc.LTM Mar 2026$15.36M USD+17.2%+61.5%5.7%
TTRXTurn Therapeutics Inc.LTM Mar 2026$365.75K USD———
Peer median (excluding HROW) —+23.6%+34.9%1752.3%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.48M88.6M130.19M199.61M272.3M
Cost of Revenue18.21M25.38M39.64M49.25M67.93M
Gross Profit54.26M63.21M90.55M150.37M204.37M
Gross Margin74.9%71.3%69.6%75.3%75.1%
Research & Development11.08M3.05M6.65M12.23M12.85M
Selling, General & Admin39.82M000152.91M
Operating Expenses52.65M61.29M90.12M141.55M165.76M
Depreciation & Amortization1.74M2.83M11.14M13.05M18.91M
EBITDA5.1M(3.94M)11.95M22.13M41.36M
EBITDA Margin7.0%-4.4%9.2%11.1%15.2%
Operating Income1.61M1.92M431K8.82M38.61M
Operating Margin2.2%2.2%0.3%4.4%14.2%
Interest Income00000
Interest Expense5.44M7.24M21.32M22.79M24.18M
Other Income / Expenses(19.49M)(15.93M)(24.14M)(26.14M)(40.33M)
Income Before Tax(17.87M)(14.01M)(23.71M)(17.32M)(1.72M)
Pre-Tax Margin-24.7%-15.8%-18.2%-8.7%-0.6%
Income Tax Expense133K75K701K161K3.42M
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Net Margin-24.8%-15.9%-18.7%-8.8%-1.9%
EPS (Basic)(0.69)(0.51)(0.75)(0.49)(0.14)
EPS (Diluted)(0.69)(0.51)(0.75)(0.49)(0.14)
Weighted Avg Shares26.76M27.46M32.62M35.65M36.76M
Weighted Avg Shares (Diluted)26.76M27.46M32.62M35.65M36.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.